YOLFTbeta
SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc.

SGP · NASDAQ · Healthcare / Biotechnology

32.88USD-0.44 (-1.32%)

Price History

Full chart

Market Stats

Previous Close33.32
Open33.88
Day Range32.12 – 33.88
52-Week Range17.06 – 32.44
Volume39.46K
Market Cap905.44M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.68
Dividend Yield0.00%
50-Day Avg25.43
200-Day Avg23.98

About

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Patrick H. Mooney
  • Employees76
  • Headquarters15326 Alton Parkway, Irvine, CA, United States, 92618, USA
  • Websitehttps://www.spyglasspharma.com

Leadership

  • Dr. Malik Y. Kahook M.D.Co-Founder, President, Chief Medical Officer & Executive Chairman · b. 1975
  • Mr. Patrick H. MooneyCEO & Director · b. 1974
  • Dr. Chetan Pujara Ph.D.Chief Research & Development Officer · b. 1970
  • Mr. Glenn SussmanCo-founder & Chief Technology Advisor · b. 1964
  • Dr. Jean-Frederic Viret Ph.D.Chief Financial Officer · b. 1966
  • Mr. James Robert Dennewill Jr.Chief Operating Officer · b. 1981
  • Ms. Shannon Trevino J.D.General Counsel
  • Mr. Mike PinderVice President of Marketing
  • Ms. Rachel GiletteVice President of Human Resources
  • Mr. Paul Yoo O.D.Senior Vice President of Clinical Development

Financials

Income Statement

Currency: USD2023-12-312024-12-312025-12-31
Total Revenue000
Cost of Revenue--612.00K
Gross Profit---612.00K
Operating Expense--40.84M
Operating Income-14.23M-27.06M-41.45M
EBITDA-14.11M-26.79M-39.26M
Net Income-13.32M-29.16M-39.87M
R&D9.96M19.98M28.64M

Balance Sheet

Currency: USD2023-12-312024-12-312025-12-31
Total Assets41.15M23.32M115.87M
Total Liabilities74.13M83.79M214.70M
Total Equity-32.99M-60.47M-98.84M
Cash15.85M16.27M96.36M
Total Debt--1.58M
Net Debt---94.78M

Cash Flow

Currency: USD2023-12-312024-12-312025-12-31
Operating Cash Flow-12.28M-22.03M-32.70M
Investing Cash Flow---11.79M
Financing Cash Flow39.77M185.00K124.58M
Capital Expenditure216.54K1.99M789.00K
Free Cash Flow-12.49M-24.02M-33.49M
FCF to OCF101.76%109.04%102.41%

Earnings

Report DateMar 27, 2026May 14, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-0.48-0.36-0.48-0.66
EPS Actual-0.38-0.69-0.59-
Surprise21.49%-91.67%-22.92%-
Timing-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap905.44M
Enterprise Value709.34M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book4.05
EPS-1.68
Book Value6.95
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-61.09M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-67.71%
Return on Assets-37.23%
Shares Outstanding33.45M
Shares Float6.50M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
94.69%
Insiders
4.28%
Retail / Other
1.03%

Top Institutional Holders

  • RA Capital Management, LLC
    8.02M23.98%
  • NEA Management Company, LLC
    7.39M22.10%
  • Sands Capital Ventures, LLC
    2.50M7.47%
  • Samsara BioCapital, LLC
    2.11M6.31%
  • T. Rowe Price Associates, Inc.
    704.44K2.11%
  • Vestal Point Capital LP
    666.76K1.99%
  • JPMorgan Chase & Co
    577.11K1.73%
  • Deerfield Management Co
    550.00K1.64%
  • Millennium Management LLC
    507.26K1.52%
  • Aberdeen Group PLC
    493.08K1.47%
  • Vanguard Capital Management, LLC
    434.81K1.30%
  • Franklin Templeton Inc
    300.00K0.90%
  • BlackRock Inc
    144.74K0.43%
  • Affinity Asset Advisors, LLC
    131.59K0.39%

Top Fund Holders

  • JPMorgan Small Cap Growth A
    477.73K1.43%
  • Vanguard MStar Total Stk Mkt Idx Invest
    317.05K0.95%
  • abrdn Healthcare Investors
    221.97K0.66%
  • T. Rowe Price New Horizons
    217.75K0.65%
  • JPMorgan Small Cap Blend A
    153.58K0.46%
  • abrdn Healthcare Opportunities
    135.44K0.40%